Using this agent, we previously showed that inhibition of the NF-κB pathway led to a potent induction of apoptosis in renal cell cancer, bladder cancer, and prostate cancer cells [8-10], suggesting that the regulation of NF-κB may be a potent therapeutic target for urogenital cancer. The gene discussed is NFKB1; the disease is prostate carcinoma.